How I treat relapsed myeloma

Area of Science:

• Hematology
• Oncology
• Internal Medicine

Background:

• Multiple myeloma (MM) is a plasma cell malignancy with a poor prognosis.
• Novel agents have improved front-line therapy, but relapse remains a significant challenge.
• Effective management of relapsed MM is crucial for improving patient survival and quality of life.

Observation:

• Treatment decisions for relapsed MM depend on symptom status, disease progression, and prior therapies.
• Asymptomatic relapse may allow for delayed treatment, while symptomatic relapse necessitates immediate intervention.
• Retreatment strategies, sequential drug approaches, and autologous or allogeneic stem cell transplantation are key considerations.

Findings:

• Prompt rescue therapy is indicated for symptomatic relapse, advanced disease, or significant paraprotein increase.
• Sequential treatment approaches considering drug synergism can be beneficial for successive relapses.
• Second autologous stem cell transplantation (ASCT) may benefit patients with a long response duration (>2 years) to the first ASCT.
• Allogeneic transplantation is considered for patients with aggressive disease or poor cytogenetics relapsing within 2 years of ASCT.

Implications:

• Personalized treatment strategies are essential for managing relapsed multiple myeloma.
• Continued therapy until progression, especially with safe regimens, is recommended for advanced cases.
• Clinical trials investigating novel agents offer hope for patients with relapsed or refractory MM.
• Exploring newer drugs and clinical trial participation is encouraged for optimal patient management.